AU2001282389A1 - Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists - Google Patents

Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists

Info

Publication number
AU2001282389A1
AU2001282389A1 AU2001282389A AU8238901A AU2001282389A1 AU 2001282389 A1 AU2001282389 A1 AU 2001282389A1 AU 2001282389 A AU2001282389 A AU 2001282389A AU 8238901 A AU8238901 A AU 8238901A AU 2001282389 A1 AU2001282389 A1 AU 2001282389A1
Authority
AU
Australia
Prior art keywords
leu
pparγ
disease
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282389A
Other languages
English (en)
Inventor
Johan Auswerx
Stephane Rocchi
Joseph Vamecq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
ASS POUR LE DEV de la RECH EN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASS POUR LE DEV de la RECH EN filed Critical ASS POUR LE DEV de la RECH EN
Publication of AU2001282389A1 publication Critical patent/AU2001282389A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001282389A 2000-06-29 2001-06-28 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists Abandoned AU2001282389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21492400P 2000-06-29 2000-06-29
US60/214,924 2000-06-29
PCT/IB2001/001581 WO2002000611A2 (en) 2000-06-29 2001-06-28 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists

Publications (1)

Publication Number Publication Date
AU2001282389A1 true AU2001282389A1 (en) 2002-01-08

Family

ID=22800931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282389A Abandoned AU2001282389A1 (en) 2000-06-29 2001-06-28 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists

Country Status (6)

Country Link
US (1) US20040082623A1 (ja)
EP (1) EP1294681A2 (ja)
JP (1) JP2004501896A (ja)
AU (1) AU2001282389A1 (ja)
CA (1) CA2415873A1 (ja)
WO (1) WO2002000611A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
JP2007055900A (ja) * 2003-12-15 2007-03-08 Ajinomoto Co Inc 炎症性疾患の治療及び予防用医薬組成物
EP1988892A2 (en) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ITTO20060282A1 (it) * 2006-04-14 2007-10-15 Univ Degli Studi Torino Mezzo di coltura e composizione farmaceutica per la rigenerazione del tessuto cartilagineo relativo procedimento relativi usi e prodotti
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079260A (en) * 1989-06-22 1992-01-07 Nova Pharmaceutical Corporation Method for treating inflammation and compounds and compositions suitable for use therein

Also Published As

Publication number Publication date
WO2002000611A8 (en) 2003-05-15
CA2415873A1 (en) 2002-01-03
WO2002000611A9 (en) 2004-04-15
US20040082623A1 (en) 2004-04-29
EP1294681A2 (en) 2003-03-26
JP2004501896A (ja) 2004-01-22
WO2002000611A3 (en) 2002-05-30
WO2002000611A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
US7544714B2 (en) Lipid-amino acid conjugates and methods of use
US20170121261A1 (en) Diglycidic ether derivative therapeutics and methods for their use
US20160009748A1 (en) Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
RU2669999C2 (ru) Полипептиды
US20170239216A1 (en) Small molecule inhibitors of n-terminus activation of the androgen receptor
KR20060073929A (ko) 질환 치료에 유용한 세미카르바지드 민감성 아민옥시다제(ｓｓａｏ) 및 ｖａｐ-1 매개 유착의 억제제
US5688992A (en) O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
JP2007516434A (ja) リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用
JP2002517423A (ja) シクロオキシゲナーゼ−２の多結合インヒビター
US20040082623A1 (en) Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
EP0457701A1 (fr) Nouveaux dérivés de médiateurs endogènes, leurs sels, procédé de préparation, applications, et compositions les renfermant
EP0046113B1 (fr) Nouveaux peptides et leur application en thérapeutique
US20040082664A1 (en) Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition
Sternbach Modulators of peroxisome proliferator-activated receptors (PPARs)
EP0395529B1 (fr) Nouveau dérivé d'hydroxyphénéthylamine et ses sels, procédé de préparation, application à titre de médicaments et utilisation comme outil pharmacologique spécifique
Peiretti et al. A novel N-substituted valine derivative with unique PPARγ binding properties and biological activities
JPH10502454A (ja) Ｎｕｃ阻害剤のスクリーニング
JP2016516752A (ja) アテローム性動脈硬化症の治療および予防のための環状ペプチドの使用
EP4453004A1 (en) Compounds
FR2853911A1 (fr) Gene induit par l'insuline, comme cible therapeutique dans le diabete
WO2002020527A1 (en) Soluble compounds for the inhibition of multidrug resistance and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application